How do the CANMAT 2023 guidelines address treatment-resistant depression in adults?
Open MIND June 19, 2026 DOI: 10.5281/zenodo.20760604 via OpenAlex
Summary
The CANMAT 2023 guidelines for treatment-resistant depression outline evidence-based pharmacological and non-pharmacological strategies, including repetitive transcranial magnetic stimulation (rTMS), lithium, and modest use of ketamine and esketamine. The guidelines emphasize that while these options are supported by current evidence, further studies are needed to determine their long-term efficacy. The recommendations aim to provide clinicians with a structured approach to managing depression that does not respond to standard treatments.
Study at a glance
| Characteristics | Clinical practice guidelines Peer reviewed |
|---|---|
| Population | Adults with TRD |
| Keywords | Depression economics Variety cybernetics Medline Mental health Disease |
| Key finding | The CANMAT 2023 guidelines recommend rTMS, lithium, and limited use of ketamine and esketamine for treatment-resistant depression, while noting the need for more research on long-term outcomes. |
Abstract
The CANMAT 2023 guidelines for treatment-resistant depression incorporate a variety of pharmacological and non-pharmacological strategies, reflecting evidence-based options like rTMS, lithium, and modest use of ketamine and esketamine, while highlighting the need for further studies on long-term efficacy.